A retrospective study on the prevalence of anti-phospholipid antibodies, thrombotic events and cutaneous signs of vasculopathy in 173 hospitalized COVID-19 patients
CONCLUSIONS: Anti-phospholipid antibodies cannot be considered responsible for hypercoagulability and thrombotic events in COVID-19 patients. In COVID-19 patients, livedo reticularis and acrocyanosis do not appear to be cutaneous manifestations of APS.PMID:34541915 | DOI:10.1177/20587384211042115
This study aimed to understand the extent to which cannabis-related risk perception and COVID-19-related health worries were associated with the reported reduction in sharing cannabis smoking products to mitigate the risk of the coronavirus transmission or infection. This association was tested in two different periods in terms of toughness of national lockdown policy imposed in the first months of the pandemic in Israel. The study population included adult recreational cannabis users who completed one of the two online cross-sectional surveys dedicated to COVID-19 and the cannabis use situation in Israel in the first h...
“Last March, I was working in a small primary care practice on the west side of Denver. COVID-19 came to town. On Thursday, March 12, we were told the schools would be closing. On Friday, we were told that clinic staff had to wear masks — and the clinic had to start testing patients forRead more …I was thinking about retiring, and COVID-19 gave me a push [PODCAST] originally appeared inKevinMD.com.
Both Iterion and Moleculin are moving their drug candidates through the regulatory pipeline.
The U.S. Food and Drug Administration has given the O.K. to Covid-19 vaccine "booster" shots made by Cambridge biotech Moderna Inc. Moderna (Nasdaq: MRNA) is now able to make and distribute boosters — third shots identical to each of the first two in the series, but half the amount — for patients 65 and older, adults with underlying medical conditions and adults who are at a high risk for Covid-19 because of their occupati ons or time in institutional settings. The decision comes a few days…